Products - Head and neck cancers | Topic | NICE

Showing 4 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 April 2026
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma [ID6477]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 April 2026
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 December 2026
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC